ALEMBIC LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.4 INR | +0.43% |
|
+6.69% | +28.57% |
| May. 30 | Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets | MT |
| May. 13 | Alembic Limited Recommends Dividend for the Year Ended 31 March, 2024 | CI |
| Sales 2022 | 782M 9.37M | Sales 2023 | 1.27B 15.24M | Capitalization | 15.22B 182M |
|---|---|---|---|---|---|
| Net income 2022 | 2.22B 26.61M | Net income 2023 | 1.91B 22.83M | EV / Sales 2022 | 23.4 x |
| Net cash position 2022 | 270M 3.24M | Net cash position 2023 | 464M 5.55M | EV / Sales 2023 | 11.6 x |
| P/E ratio 2022 |
8.37
x | P/E ratio 2023 |
7.99
x | Employees | 271 |
| Yield 2022 |
2.49% | Yield 2023 |
3.71% | Free-Float | 27.91% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.52% | ||
| 1 week | +6.69% | ||
| Current month | +4.23% | ||
| 1 month | +17.33% | ||
| 3 months | +22.70% | ||
| 6 months | +24.89% | ||
| Current year | +28.57% |
1 week
108.02
118.30
1 month
86.50118.30
Current year
78.20118.30
1 year
71.00118.30
3 years
55.52139.35
5 years
25.00143.30
10 years
21.75143.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 88-07-01 | |
Rasesh J. Shah
DFI | Director of Finance/CFO | - | 14-08-12 |
| Chairman | 76 | 67-08-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 67-08-19 | |
| Chief Executive Officer | 69 | 88-07-01 | |
| Director/Board Member | 44 | 13-04-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 116.4 | +0.43% | 21 418 |
| 24-07-02 | 115.9 | +1.89% | 125,860 |
| 24-07-01 | 113.8 | +1.77% | 243,721 |
| 24-06-28 | 111.8 | +0.56% | 72,978 |
| 24-06-27 | 111.2 | +1.80% | 197,881 |
Delayed Quote Bombay S.E., July 03, 2024 at 01:36 am EDT
More quotes
Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +28.57% | 357M | |
| +27.96% | 25.71B | |
| +14.79% | 24.63B | |
| +1.25% | 24.96B | |
| -20.72% | 23.51B | |
| +2.78% | 19.59B | |
| +31.37% | 19.75B | |
| +3.78% | 19.16B | |
| +45.86% | 17.79B | |
| -8.79% | 14.74B |
- Stock Market
- Equities
- ALEMBICLTD Stock
